{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-087841","form_type":"8-K","ticker":"LITS","cik":"0001262104","company_name":"Lite Strategy, Inc.","filed_at":"2024-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.417233+00:00","generated_at":"2026-05-31T14:59:19.061271+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MEI Pharma halts voruciclib clinical development, begins strategic alternatives review","bullets":["Board unanimously decided to evaluate strategic alternatives including potential transactions or orderly wind-down.","Clinical development of voruciclib discontinued; only certain non-clinical activities will continue.","Company intends to maximize value of its assets; no specific timeline or deal announced.","Corporate presentation attached as Exhibit 99.1 details voruciclib program status."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-087841","json":"https://secwatch.observer/filing/0000950170-24-087841.json","markdown":"https://secwatch.observer/filing/0000950170-24-087841.md","text":"https://secwatch.observer/filing/0000950170-24-087841.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1262104/000095017024087841/0000950170-24-087841-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1262104/000095017024087841/meip-20240730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T14:59:19.061271+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}